Upcoming ISG Provider Lens^® report will examine how providers enable digital, AI-driven transformation across the life sciences value chain

Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, has launched a research study examining IT service providers and contract research organizations (CROs) across key digital and operational areas in the life sciences domain.

The study results will be published in a comprehensive ISG Provider Lens^® report, called Life Sciences Digital Services, scheduled to be released in April 2026. The report will cover companies offering services such as digital clinical development, patient engagement, manufacturing and supply chain, pharmacovigilance and regulatory affairs and commercial operations, including the capabilities of CROs.

Enterprise buyers will be able to use information from the report to evaluate their current vendor relationships, potential new engagements and available offerings, while ISG advisors use the information to recommend providers to the firm’s buy-side clients.

Life sciences enterprises are turning to strategic providers, including CROs, to unify fragmented data and modernize legacy systems. As innovation costs rise, organizations are prioritizing scalable digital strategies built on cloud data platforms, Good x Practice (GxP)-compliant AI and interoperable systems to strengthen core operations. Factors such as platform consolidation, patient-centric design and hybrid trial models are accelerating digital adoption among enterprises in this domain, supported by clearer regulations for decentralized trials and remote monitoring.

“Enterprises are moving decisively from experimentation to true, enterprise-grade digital transformation,” said Iain Fisher, director at ISG. “They are rapidly adopting advanced technologies such as GenAI copilots to support critical life sciences processes including protocol design, labeling and safety reporting.”

ISG has distributed surveys to more than 80 providers. Working in collaboration with ISG’s global advisors, the research team will produce eight quadrants representing the digital services that the typical life sciences enterprise is buying, based on ISG’s experience working with its clients. The eight quadrants are:

• Clinical Development (Service Providers), evaluating providers’ capabilities in facilitating efficient, compliant and data-driven drug development. They are further examined on their ability to accelerate trial timelines, improve data integrity and enable decentralized and hybrid trial models.
• Patient Engagement (Service Providers), assessing providers delivering omnichannel platforms, mobile health tools and digital therapeutics that enhance patient education, adherence and retention. Providers in this space should combine life sciences expertise with robust digital platforms.
• Manufacturing and Supply Chain (Service Providers), covering providers that can facilitate digitally connected, compliant and resilient operations across drug and device manufacturing. They should demonstrate expertise in process automation, predictive maintenance and quality control.
• Pharmacovigilance and Regulatory Affairs — Digital Evolution (Service Providers), evaluating providers offering AI-enabled case processing, signal detection and regulatory intelligence solutions. They are assessed on their ability to comply with varied life sciences regulatory standards and their proficiency in workflow automation.
• Commercial Operations — Digital Evolution (Service Providers), evaluating providers’ potential and strategic vision in commercial operations. Providers should focus on how their technology enables data-driven, omnichannel engagement and commercial excellence for life sciences organizations.
• Clinical Development (CROs), examining CROs delivering digitally enabled, decentralized and hybrid clinical trial services. CROs should combine scientific depth with digital innovation to provide patient-centric clinical research outcomes.
• Patient Engagement (CROs), covering CROs providing digital and behavioral science-based engagement tools that improve patient recruitment, onboarding and retention. Key evaluation areas include mobile applications, wearables and AI-driven analytics that enable personalized, real-time interaction with patients.
• Pharmacovigilance and Regulatory Affairs — Digital Evolution (CROs), assessing CROs’ ability and effectiveness in managing drug safety, compliance and global submissions. They need to demonstrate success in reducing case turnaround times and enhancing submission accuracy.

Geographically focused reports from the study will cover the global life sciences digital services market and examine products and services available worldwide. ISG analysts Rohan Sinha and Sneha Jayanth will serve as authors of the report.

A list of identified providers and vendors and further details on the study are available in this digital brochure. Companies not listed as digital service providers in the life sciences domain can contact ISG and ask to be included in the study.

All 2025 ISG Provider Lens^® evaluations feature expanded customer experience (CX) data that measures actual enterprise experience with specific provider services and solutions, based on ISG’s continuous CX research.

About ISG Provider Lens^® Research

The ISG Provider Lens^® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251208138954/en/

Enterprises are moving from experimentation to true digital transformation. They are rapidly adopting advanced technologies such as GenAI copilots to support critical life sciences processes including protocol design, labeling and safety reporting.